Crossmark

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Published Online: 2019-07-24

Published Print: 2019-12

Authors

Sabio, Erich

Chan, Timothy A.
Funding

Funding for this research was provided by:

Pershing Square Sohn Cancer Research Alliance (.)
License Information

Text and Data Mining valid from 2019-07-24

Version of Record valid from 2019-07-24
More Information

Article History

First Online: 24 July 2019

Competing interests

: TAC is an inventor on provisional patent application (62/569,053) submitted by Memorial Sloan Kettering Cancer Center (MSKCC) that covers use of tumor mutational burden as a predictive biomarker for cancer immunotherapy. TAC is an inventor on a PCT patent application (PCT/US2015/062208) filed by MSKCC, relating to the use of tumor mutational burden in lung cancer immunotherapy that has been licensed to Personal Genome Diagnostics, and MSKCC and TAC receive royalties. TAC is a co-founder of Gritstone Oncology and holds equity. TAC has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. TAC acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai.

Document is current